Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
Agile Therapeutics, a women's healthcare company, announced that its CEO, Al Altomari, will participate in a panel at Maxim Group’s M-Vest Virtual Conference on August 13, 2020, at 10:00 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agile Therapeutics, a women's healthcare company, announced that its CEO, Al Altomari, will participate in a panel at Maxim Group’s M-Vest Virtual Conference on August 13, 2020, at 10:00 a.m. Eastern Time. This event will be moderated by Jason McCarthy, a biotechnology analyst at Maxim Group. Agile Therapeutics focuses on providing innovative contraceptive options, including its non-daily prescription system, Twirla. For registration details, visit here.
Details
News Market Reaction – AGRX
The recorded move for AGRX in the trading session of this news was -7.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a panel discussion as part of Maxim Group’s M-Vest Virtual Conference Series: Leading Innovators in Women’s Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020. The panel will be moderated by Jason McCarthy, PhD, lead biotechnology analyst at Maxim Group.
Webcast Details:
- Date and Time: Thursday, August 13, 10:00 a.m. Eastern time
- Registration Link: https://bit.ly/2DlgeRW
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.
Follow Agile on LinkedIn and Twitter: @AgileTher.
Contact:
Matt Riley
Head of Investor Relations
mriley@agiletherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.